Surgical management of secondary hyperparathyroidism in dialysis patients in Senegal

被引:2
|
作者
Faye, Maria [1 ,2 ]
Keita, Niakhaleen [1 ]
Lemrabott, Ahmed Tall [1 ]
Algouzmari, Ilham [1 ]
Faye, Moustapha [1 ]
Mbengue, Mansour [1 ]
Diagne, Seynabou [1 ]
Ba, Bacary [1 ]
Dieng, Ameth [1 ]
Ba, Mamadou Aw [1 ]
Ka, El Hadj Fary [1 ]
机构
[1] Cheikh Anta Diop Univ, Dept Nephrol, Dakar, Senegal
[2] Aristide Le Dantec Univ Hosp, Dept Nephrol, Dakar, Senegal
关键词
TOTAL PARATHYROIDECTOMY;
D O I
10.4103/1319-2442.344763
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Secondary hyperparathyroidism (SHPT) is a common complication of end-stage renal disease. Surgical management occurs in severe forms and/or unresponsive medical treatment. The aim of this study was to outline the indications of parathyroidectomy and its evolution after surgical approach. It was a five-year multicenter backward study in Otorhinolaryngology Department of Fann Hospital and four dialysis centers in Dakar. We include all patients with SHPT who underwent surgery. Preoperative clinical and paraclinical parameters, clinical-biological evolution, and histology findings of the resected parathyroid specimen were collected. Out of 58 patients with hyperparathyroidism, 18 patients required parathyroidectomy, corresponding to a prevalence of 31%. Mean age of patients was 46.6 +/- 15.29 years and sex ratio 0.61. Mean duration on dialysis was 44.4 +/- 30 months. Ten patients (55.56%) had bone pain and nine patients (50%) had joint pain. Mean serum calcium was 97.27 +/- 8.66 mg/L. Mean blood phosphorus levels were 40.47 +/- 9.99 mg/L. Mean iPTH rate was 1493.22 +/- 1014.93 ng/mL, with a maximum of 5000 ng/mL (77N). Mean value of 25-OH Vitamin D was 32.89 +/- 16.02 ng/mL. Parathyroidectomy was indicated after failure of medical treatment with persistence of a serum intact parathyroid hormone concentration above 800 mu g/mL in all patients. Subtotal parathyroidectomy (7/8) was performed in 11 patients (61.1%). Two patients (11.11%) benefited from a selective parathyroidectomy (3/4). Evolution was favorable for 13 patients, corresponding to a success rate of 72.2%. It was unfavorable in five patients including one patient with hypoparathyroidism and four patients with recurrent hyperparathyroidism. Surgery for patients with renal hyperparathyroidism in the era of calcimimetics continues to play an important role in selected patients and achieves efficient control of hyperparathyroidism in developing countries.
引用
收藏
页码:1424 / 1430
页数:7
相关论文
共 50 条
  • [31] Decreasing Surgical Management of Secondary Hyperparathyroidism in the United States
    Fligor, Scott C.
    Li, Chun
    Hamaguchi, Ryoko
    William, Jeffrey
    James, Benjamin C.
    JOURNAL OF SURGICAL RESEARCH, 2021, 264 : 444 - 453
  • [32] Secondary and Tertiary Hyperparathyroidism, State of the Art Surgical Management
    Pitt, Susan C.
    Sippel, Rebecca S.
    Chen, Herbert
    SURGICAL CLINICS OF NORTH AMERICA, 2009, 89 (05) : 1227 - +
  • [33] SURGICAL-MANAGEMENT OF PATIENTS WITH HYPERPARATHYROIDISM
    MARKOV, IN
    KHIRURGIYA, 1980, (08): : 86 - 92
  • [34] CORRECTION OF SEVERE SECONDARY HYPERPARATHYROIDISM IN 2 DIALYSIS PATIENTS - SURGICAL REMOVAL VERSUS PERCUTANEOUS ETHANOL INJECTION
    PAGE, B
    ZINGRAFF, J
    SOUBERBIELLE, JC
    COUTRIS, G
    SARFATI, E
    DRUEKE, T
    MOREAU, JF
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (04) : 378 - 381
  • [35] Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism
    Llach, F
    Yudd, M
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) : S45 - S50
  • [36] A NATIONAL SURVEY ON SECONDARY HYPERPARATHYROIDISM IN PAEDIATRIC PATIENTS ON CHRONIC DIALYSIS
    Verrina, E.
    Picca, S.
    Edefonti, A.
    Gianoglio, B.
    Maringhini, S.
    Pecoraro, C.
    Sorino, P.
    Vidal, E.
    Lavoratti, G.
    Ratsch, I.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1861 - 1861
  • [37] Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism
    Bover, Jordi
    Urena, Pablo
    Ruiz-Garcia, Cesar
    daSilva, Lara
    Lescano, Patricia
    del Carpio, Jacqueline
    Ballarin, Jose
    Cozzolino, Mario
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (01): : 161 - 174
  • [38] Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: The role of paricalcitol
    Cozzolino, Mario
    Galassi, Andrea
    Gallieni, Maurizio
    Brancaccio, Diego
    CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (02) : 148 - 153
  • [39] Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
    Akizawa, Tadao
    Ikejiri, Kazuaki
    Kondo, Yuichiro
    Endo, Yuichi
    Fukagawa, Masafumi
    THERAPEUTIC APHERESIS AND DIALYSIS, 2020, 24 (03) : 248 - 257
  • [40] TRENDS IN MEDICAL AND SURGICAL MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) AMONG HEMODIALYSIS PATIENTS: RESULTS FROM THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)
    Bieber, B.
    Robinson, B.
    Mariani, L.
    Jacobson, S.
    Frimat, L.
    Bommer, J.
    Pisoni, R.
    Tentori, F.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 462 - 462